Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aerie's Ophthalmic Candidate Positive in Registration Trial

by Zacks Equity Research

Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.

    Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab

    by Zacks Equity Research

    Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.

      AbbVie Down on Humira Patent Loss: Is More Damage in Store?

      by Zacks Equity Research

      AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS),

        Allergan's Irritable Bowel Drug Viberzi Approved in Canada

        by Zacks Equity Research

        Allergan plc (AGN) announced that Health Canada approved Viberzi (eluxadoline) for the treatment of adults suffering with irritable bowel syndrome with diarrhea (IBS-D)

          Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss

          by Zacks Equity Research

          Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents.

            Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review

            by Zacks Equity Research

            Aerie Pharmaceuticals, Inc. (AERI) announced that it has received notification from the FDA about the completion of the initial 60-day review of the NDA for Rhopressa

              Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

              by Zacks Equity Research

              Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.

                Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls

                by Zacks Equity Research

                Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.

                  Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan

                  by Zacks Equity Research

                  Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

                    Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View

                    by Zacks Equity Research

                    Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.

                      Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss

                      by Zacks Equity Research

                      Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.

                        Allergan (AGN) Beats Q1 Earnings & Sales; Ups 2017 View

                        by Zacks Equity Research

                        Allergan???s first-quarter earnings of $3.35 per share were above our consensus estimate of $3.32 per share.

                          Tracey Ryniec headshot

                          The Top Earnings Charts to Start the Week

                          by Tracey Ryniec

                          With so many companies reporting earnings, Tracey wades through all the noise to bring you the best charts.

                            What's in the Cards for Allergan (AGN) this Earnings Season?

                            by Zacks Equity Research

                            Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens.

                              Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up

                              by Zacks Equity Research

                              Aerie Pharmaceuticals, Inc. (AERI) posted first-quarter 2017 loss of 76 cents per share (including stock-based compensation), wider than the Zacks Consensus Estimate of a loss of 74 cents.

                                Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales

                                by Zacks Equity Research

                                Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.

                                  Allergan (AGN) Collaborates with Novartis to Treat NASH

                                  by Zacks Equity Research

                                  Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis

                                    Arpita Dutt headshot

                                    Did Pharma & Biotech M&As Pick Pace in Q1?

                                    by Arpita Dutt

                                    Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.

                                      Aerie Reports Positive Data on Ophthalmic Drug Rhopressa

                                      by Zacks Equity Research

                                      Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.

                                        Arpita Dutt headshot

                                        5 Drug Stocks for Your Portfolio this World Health Day

                                        by Arpita Dutt

                                        With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.

                                          Allergan (AGN) Presents Mixed Depression Data on Botox

                                          by Zacks Equity Research

                                          Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).

                                            Paratek (PRTK) Stock Continues to Rise on Positive Results

                                            by Zacks Equity Research

                                            Paratek Pharmaceuticals, Inc.'s (PRTK) shares are up more than 22% since it announced positive results from a phase III study of its lead pipeline candidate

                                              Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline

                                              by Zacks Equity Research

                                              Acorda Therapeutics, Inc. (ACOR) recently announced plans to reduce its workforce by approximately 20%.

                                                Why Is Allergan (AGN) Down 2.2% Since the Last Earnings Report?

                                                by Zacks Equity Research

                                                Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Teva's Austedo Gets FDA Nod for Huntington Disease Treatment

                                                  by Zacks Equity Research

                                                  Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that the FDA has approved its investigational drug, Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington disease (HD).